MaxCyte, Inc. (LON:MXCT – Get Free Report) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 330.81 ($4.33) and traded as low as GBX 300 ($3.92). MaxCyte shares last traded at GBX 300 ($3.92), with a volume of 15,500 shares traded.
MaxCyte Trading Up 0.3 %
The company has a market capitalization of £315.27 million, a P/E ratio of -1,153.85 and a beta of 1.13. The company has a 50-day simple moving average of GBX 330.71 and a 200 day simple moving average of GBX 336.38. The company has a debt-to-equity ratio of 8.37, a quick ratio of 14.38 and a current ratio of 14.31.
About MaxCyte
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Featured Articles
- Five stocks we like better than MaxCyte
- Trading Stocks: RSI and Why it’s Useful
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- What is Put Option Volume?
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- Quiet Period Expirations Explained
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
